Stem Cell Transplant’s Impact on Relapsed Myeloma
When proteasome inhibitors (like bortezomib) and immunomodulators (like lenalidomide) were introduced in the early 2000s…
Browsing: Multiple Myeloma News
Blood Cancer Phase I NK Cell Clinical Trial Shows Durable Complete Responses
An immunotherapy called natural killer (NK) cells can be used with your own NK cells…
For newly diagnosed MM patients: the importance of lenalidomide maintenance therapy post Transplant
BY PAUL KLEUTGHEN The newly diagnosed MM patient will most likely be overwhelmed not only…
FDA Panel Recommends Approval for Novartis CAR T Cell Treatment in Leukemia
The Food and Drug Administration panel opened the door to widespread use of CAR T…
Second Study Shows Kyprolis® Improves Overall Survival for Relapsed/Refractory Myeloma
Final results from the Phase III ASPIRE study were published by Amgen showing that carfilzomib…
Patient Power: Progress in Immunotherapies and Precision Medicine
Dr. Hearn Jay Cho of Mount Sinai Hospital joined Andrew Schorr of Patient Power at…
MCRI Update: CAR T Cell Research, University of Würzburg
The Myeloma Crowd funded two key immunotherapy projects as part of the Myeloma Crowd Research…
EHA 2017: Elotuzumab Shows Long-Term Impact in 4-Year Study Follow-Up
Bristol-Myers Squibb presented four year updated data from their ELOQUENT-2 Trial, a trial enrolling 646…
FDA Places Keytruda Multiple Myeloma Studies on Hold
Merck & Co announced today that the FDA had placed a clinical hold on three…
EHA 2017: Newly Diagnosed Myeloma
Today many newly diagnosed myeloma patients will receive induction therapy and then go to stem…
EHA 2017: The Nature of Long Remissions
“I still haven’t found what I’m looking for.” U2 What makes one patient’s remission longer…
EHA 2017: The Art of Treating Multiple Myeloma
“The arrival of new effective drugs in such a short period of time is making…
EHA 2017: Myeloma Treatment for the Elderly or Transplant Ineligible
Myeloma therapy is getting better for elderly patients according to Graham Jackson, MD and Professor…
EHA 2017: Managing Myeloma Drug Side Effects
Today is the first day of the European Hematology Conference in Madrid, Spain. We will…
ASCO 2017: Three Studies for Newly Diagnosed Multiple Myeloma
Three studies were reported on at the recent ASCO 2017 conference that were specific to…
ASCO 2017: CAR T Cell Therapy Shows Incredible Results in Myeloma
At the recent ASCO 2017 conference, CAR T cell therapy demonstrated unprecedented results in several…
ASCO 2017: New Myeloma Bone Strengthener Shows Equal Benefit Compared to Zoledronic Acid
At the recent American Society of Clinical Oncology (ASCO) conference, Amgen presented data from a…
Artificial Virus May Become Foundation for Innovative Cancer Treatment
Swiss scientists from the University of Geneva (UNIGE), Switzerland, and the University of Basel have…
Keytruda, Pomalidomide and Dex Combination May Provide Impact for Relapsed/Refractory Myeloma Patients
The triple combination of pembrolizumab (Keytruda), pomalidomide and low dose dexamethasone was recently studied at the…
Minimal Residual Disease Negativity Becomes the New End Point in Myeloma Therapy
In a recent ASCO article by French myeloma specialists Jean-Luc Harousseau and Herve Avet-Loisea and…
Relapse of Multiple Myeloma: What Happens Next?
BY PAUL KLEUTGHEN This is a question that many of us ask ourselves after our…
Curcumin Gets Positive Results in Small MGUS and Smoldering Study
BY ERIC HANSEN Curcumin is beneficial to MGUS/SMM patients according to a small study published…
New Drug that Redirects Immune Cells Towards Myeloma Tumor Cells Cleared by FDA for Clinical Trial
The FDA has approved a new drug application by Glenmark Pharmaceuticals to begin a phase…
New Drug GMI-1271 May Help Velcade Work Again in Relapsed Myeloma
Velcade is an effective treatment for multiple myeloma, but some patients’ myeloma can become resistant…
Comparing Myeloma Minimal Residual Disease Tests: EuroFlow vs. New MSKCC Test
Evaluating myeloma patients after treatment with more sensitive testing to see how much disease is…
Myeloma 101: Vaccinations After Myeloma Stem Cell Transplant
BY PAUL KLEUTGHEN Should myeloma patients get re-vaccinated after stem cell transplant? Experts say there…
An Algorithm to Predict GvHD Post Allogeneic Stem Cell Transplants
BY PAUL KLEUTGHEN Some of us, myeloma patients as well as our caregivers and families,…
Sugar’s Smoke Screen and Cancer Cell Immunity
Researchers may have a sweet new way to help the immune system go after cancer…
Preventing Graft Vs. Host for Allogeneic (Donor) Stem Cell Transplant
City of Hope researchers led by Defu Zeng, professor of diabetes immunology and hematopoietic cell…
Novartis Shows Commitment to CAR T Cell Strategy
In August of last year, it was reported that Novaris was integrating its separate gene…
All you ever wanted to know about Immunomodulators (IMiDs) for Multiple Myeloma
BY PAUL KLEUTGHEN All of us are, most likely, familiar with products such as Thalomid,…
Progress in the Development of ‘Liquid Biopsies’ in Multiple Myeloma
BY PAUL KLEUTGHEN Several months ago the Broad Institute (a collaboration between MIT and the…
A New Bone Strengthener for Myeloma Patients
Multiple myeloma patients frequently have skeletal-related issues: spinal cord compression, fractures, surgeries and radiation to…
Halted Selinexor Clinical Trials Now Resume in Multiple Myeloma
On March 10, 2017, the FDA put a hold on all Selinexor clinical trials from…
Uncovering MGUS Mysteries: Should We Be Screening More for MGUS?
In the over 50 years of research since Dr. Robert Kyle, MD of the Mayo…
Aldevron Licenses Minicircle Technology for CAR T Cell Myeloma Treatments In Collaboration with the Myeloma Crowd
BY JAMES BROWN Aldevron to produce minicircles to support cell therapy applications Aldevron, along with…
Mayo Clinic Recommendations for Myeloma Therapy at First Relapse
BY ERIC HANSEN In a major review of treatment options and outcomes, a group of…
University of Iowa Myeloma Researchers Find Vitamin C Mega Doses Kills Myeloma Cells
As seen on Research and Economic Development, University of Iowa Whether in the form of…
Beneficial Cytoxan
BY JIM OMEL, MD There is a hierarchy in reporting information from the American Society…
New Inhibitor Tested by Mayo Clinic Helps Immune System Kill Myeloma Cells
Myeloma cells can be insidious and survive not only because they over-proliferate but because they…
New Inhibitors Advance New Combinations in Myeloma Research
Researchers at at Monash University and Peter MacCallum Cancer Centre in Australia have identified for…
Rabbit Virus Eliminates Myeloma Cells In Mouse Models
A rabbit virus that was used to control the Australian rabbit population in the 1950’s…
Advances in Precision Medicine in Multiple Myeloma
Brian Van Ness, PhD and myeloma researcher at the University of Minnesota shared his expertise…
FDA Approves Lenalidomide (Revlimid) As Maintenance Therapy Post-Transplant
Extended maintenance therapy has become more popular in the treatment of multiple myeloma as more…
Takeda Teams Up With PatientsLikeMe for a Myeloma Patient Survey
Takeda Oncology, in partnership with PatientsLikeMe, would like to invite you to participate in a…
Join Our National Effort to Spread Awareness and Support for Myeloma Research in March: Myeloma Awareness Month
Multiple myeloma is a rare blood cancer with over 30,000 newly diagnosed patients annually in…
Does Response to Myeloma Therapy Impact Overall Survival?
Today, myeloma specialists and oncologists measure response to myeloma treatment with standard criteria: partial response…
Stem Cell Transplant Beats Oral Chemo Combos for Newly Diagnosed Patients
A recent article in Leukemia showed that up-front autologous transplant prolonged life for newly diagnosed…
Myeloma 101: The Difference Between Consolidation and Maintenance Therapy
Many myeloma doctors use consolidation and maintenance therapy as part of their treatment for multiple…
Natural Killer Cells Can Be Used With Standard Myeloma Therapies
The main function of natural killer (NK) cells is to destroy cells that are virally…